RU2005129109A - Замещенные производные 3-(бензоилуреидо)тиофена, способ их получения и их применение - Google Patents
Замещенные производные 3-(бензоилуреидо)тиофена, способ их получения и их применение Download PDFInfo
- Publication number
- RU2005129109A RU2005129109A RU2005129109/04A RU2005129109A RU2005129109A RU 2005129109 A RU2005129109 A RU 2005129109A RU 2005129109/04 A RU2005129109/04 A RU 2005129109/04A RU 2005129109 A RU2005129109 A RU 2005129109A RU 2005129109 A RU2005129109 A RU 2005129109A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- agonists
- phenyl
- coo
- inhibitors
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 title 2
- 229930192474 thiophene Natural products 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 45
- 239000000556 agonist Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- -1 2 -piperidinyl Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 102000004146 ATP citrate synthases Human genes 0.000 claims 1
- 108090000662 ATP citrate synthases Proteins 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 102000013585 Bombesin Human genes 0.000 claims 1
- 108010051479 Bombesin Proteins 0.000 claims 1
- 102000019432 Galanin Human genes 0.000 claims 1
- 101800002068 Galanin Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims 1
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 229940124757 MC-4 agonist Drugs 0.000 claims 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 claims 1
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 102000005630 Urocortins Human genes 0.000 claims 1
- 108010059705 Urocortins Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 239000003392 amylase inhibitor Substances 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- LURYMYITPCOQAU-UHFFFAOYSA-N benzoyl isocyanate Chemical class O=C=NC(=O)C1=CC=CC=C1 LURYMYITPCOQAU-UHFFFAOYSA-N 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 208000020450 carbohydrate metabolism disease Diseases 0.000 claims 1
- 150000001805 chlorine compounds Chemical class 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 208000017745 inborn carbohydrate metabolic disease Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 1
- 230000002474 noradrenergic effect Effects 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 229940076155 protein modulator Drugs 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- DKGYESBFCGKOJC-UHFFFAOYSA-N thiophen-3-amine Chemical class NC=1C=CSC=1 DKGYESBFCGKOJC-UHFFFAOYSA-N 0.000 claims 1
- 239000000777 urocortin Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
- C07D333/44—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms attached in position 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10306502A DE10306502B4 (de) | 2003-02-17 | 2003-02-17 | Substituierte 3-(Benzoylureido)-thiophenderivate und sie enthaltende Arzneimittel |
| DE10306502.4 | 2003-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005129109A true RU2005129109A (ru) | 2006-01-27 |
Family
ID=32841675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005129109/04A RU2005129109A (ru) | 2003-02-17 | 2004-02-04 | Замещенные производные 3-(бензоилуреидо)тиофена, способ их получения и их применение |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1597247B1 (https=) |
| JP (1) | JP4589301B2 (https=) |
| KR (1) | KR20050105470A (https=) |
| CN (1) | CN1751036A (https=) |
| AR (1) | AR043179A1 (https=) |
| AT (1) | ATE402160T1 (https=) |
| AU (1) | AU2004212054A1 (https=) |
| BR (1) | BRPI0407552A (https=) |
| CA (1) | CA2516269A1 (https=) |
| CO (1) | CO5690549A2 (https=) |
| DE (2) | DE10306502B4 (https=) |
| HR (1) | HRP20050715A2 (https=) |
| MA (1) | MA27657A1 (https=) |
| MX (1) | MXPA05008331A (https=) |
| NO (1) | NO20054168L (https=) |
| PE (1) | PE20050221A1 (https=) |
| PL (1) | PL376753A1 (https=) |
| RU (1) | RU2005129109A (https=) |
| TW (1) | TW200505892A (https=) |
| WO (1) | WO2004072060A1 (https=) |
| ZA (1) | ZA200505487B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055462A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006113650A1 (en) * | 2005-04-18 | 2006-10-26 | Khan Saeed R | Design and synthesis of novel tubulin polymerization inhibitors: bonzoylphenyluria (bpu) sulfur analogs |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| WO2020261144A1 (en) * | 2019-06-28 | 2020-12-30 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3034004A1 (de) * | 1980-09-10 | 1982-04-22 | Hoechst Ag, 6000 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| HUT48880A (en) * | 1987-07-20 | 1989-07-28 | Sandoz Ag | Insecticides and acaricides comprising new n-benzoyl-n'-thienyl urea derivative as active ingredient and process for producing the active ingredients |
| DE10116768A1 (de) * | 2001-04-04 | 2002-10-10 | Aventis Pharma Gmbh | Acylphenylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| TR200401029T4 (tr) * | 2000-06-09 | 2004-06-21 | Aventis Pharma Deutschland Gmbh | Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları |
| PE20021091A1 (es) * | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| DE10215908B4 (de) * | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
| DE10215907A1 (de) * | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE10225635C1 (de) * | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
| BR0312593A (pt) * | 2002-07-11 | 2005-04-12 | Aventis Pharma Gmbh | Aciluréias substituìdas por uréia e uretano, processo para a sua produção e sua aplicação |
| RS20050019A (sr) * | 2002-07-12 | 2007-09-21 | Sanofi - Aventis Pharma Deutschland Gmbh., | Heterociklično supstituisani benzoilkarbamidi,postupak za njihovu proizvodnju i njihova primena kao leka |
| DE10246434B4 (de) * | 2002-10-04 | 2005-08-04 | Aventis Pharma Deutschland Gmbh | Carboxyalkoxy-substituierte Acyl-carboxyphenyl-harnstoffderivate und ihre Verwendung als Arzneimittel |
-
2003
- 2003-02-17 DE DE10306502A patent/DE10306502B4/de not_active Expired - Fee Related
-
2004
- 2004-02-04 HR HR20050715A patent/HRP20050715A2/xx not_active Application Discontinuation
- 2004-02-04 KR KR1020057015029A patent/KR20050105470A/ko not_active Withdrawn
- 2004-02-04 CN CNA2004800044004A patent/CN1751036A/zh active Pending
- 2004-02-04 MX MXPA05008331A patent/MXPA05008331A/es not_active Application Discontinuation
- 2004-02-04 RU RU2005129109/04A patent/RU2005129109A/ru not_active Application Discontinuation
- 2004-02-04 JP JP2006501724A patent/JP4589301B2/ja not_active Expired - Fee Related
- 2004-02-04 CA CA002516269A patent/CA2516269A1/en not_active Abandoned
- 2004-02-04 PL PL376753A patent/PL376753A1/pl not_active Application Discontinuation
- 2004-02-04 EP EP04707896A patent/EP1597247B1/de not_active Expired - Lifetime
- 2004-02-04 DE DE502004007668T patent/DE502004007668D1/de not_active Expired - Lifetime
- 2004-02-04 WO PCT/EP2004/000993 patent/WO2004072060A1/de not_active Ceased
- 2004-02-04 AT AT04707896T patent/ATE402160T1/de not_active IP Right Cessation
- 2004-02-04 AU AU2004212054A patent/AU2004212054A1/en not_active Abandoned
- 2004-02-04 BR BRPI0407552-8A patent/BRPI0407552A/pt not_active IP Right Cessation
- 2004-02-13 TW TW093103411A patent/TW200505892A/zh unknown
- 2004-02-13 AR ARP040100457A patent/AR043179A1/es unknown
- 2004-02-17 PE PE2004000163A patent/PE20050221A1/es not_active Application Discontinuation
-
2005
- 2005-07-07 ZA ZA200505487A patent/ZA200505487B/en unknown
- 2005-08-12 CO CO05080324A patent/CO5690549A2/es not_active Application Discontinuation
- 2005-08-16 MA MA28443A patent/MA27657A1/fr unknown
- 2005-09-07 NO NO20054168A patent/NO20054168L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1597247B1 (de) | 2008-07-23 |
| JP4589301B2 (ja) | 2010-12-01 |
| MXPA05008331A (es) | 2005-09-30 |
| JP2006517933A (ja) | 2006-08-03 |
| DE10306502B4 (de) | 2005-03-17 |
| DE502004007668D1 (de) | 2008-09-04 |
| NO20054168D0 (no) | 2005-09-07 |
| DE10306502A1 (de) | 2004-09-09 |
| BRPI0407552A (pt) | 2006-02-14 |
| CO5690549A2 (es) | 2006-10-31 |
| AR043179A1 (es) | 2005-07-20 |
| HRP20050715A2 (en) | 2006-09-30 |
| PE20050221A1 (es) | 2005-04-04 |
| EP1597247A1 (de) | 2005-11-23 |
| ATE402160T1 (de) | 2008-08-15 |
| AU2004212054A1 (en) | 2004-08-26 |
| NO20054168L (no) | 2005-11-11 |
| PL376753A1 (pl) | 2006-01-09 |
| MA27657A1 (fr) | 2005-12-01 |
| TW200505892A (en) | 2005-02-16 |
| CA2516269A1 (en) | 2004-08-26 |
| CN1751036A (zh) | 2006-03-22 |
| ZA200505487B (en) | 2006-08-30 |
| KR20050105470A (ko) | 2005-11-04 |
| WO2004072060A1 (de) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006131306A (ru) | Производные 7-фениламино-4-хинолон-3-карбоновой кислоты, способ их получения и их применение в качестве лекарственных средств | |
| RU2006106231A (ru) | Замещенные производные диоксида тиазолбензоизотиазола, способ их получения и их применение | |
| KR20030063462A (ko) | 디페닐 아제티디논 유도체, 이의 제조 방법, 이들화합물을 함유하는 약제 및 이의 용도 | |
| HRP20120829T1 (hr) | Karboksilne kiseline supstituirane fenilaminobenzoksazolom, postupak njihovog dobivanja i njihova upotreba kao medikamenata | |
| US6498156B2 (en) | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | |
| RU2006147245A (ru) | Замещенные производные оксазол-бензоизотиазолдиоксида, способ их получения и их применения | |
| JP2008524127A5 (https=) | ||
| RU2005121893A (ru) | Новые гетероциклические фторгликозидные производные, содержащие эти соединения лекарственные средства и их применение | |
| RU2004108120A (ru) | Комбинированные препараты из арилзамещенных производных пропаноламина с другими биологически активными веществами и их применение | |
| JP2006502247A5 (https=) | ||
| RU2005101093A (ru) | Замещенные кислотными группами дифенилазетидиноны, способ их получения, содержащие эти соединения лекарственных средства, и их применение | |
| RU2005128497A (ru) | Замещенные производные гексагидропиразино (1,2-а) пиримидин-4,7-диона, способы их получения и их применение в качестве лекарственных средств | |
| JP2007500145A5 (https=) | ||
| RU2005128499A (ru) | Замещенные у азота производные гексагидропиразино (1,2-а) пиримидин-4, 7-диона, способ их получения и их применение в качестве лекарственного средства | |
| RU2010115748A (ru) | (карбоксилалкиленфенил) фенилоксаламиды, способ их получения и их применение в качестве лекарственного средства | |
| RU2010115747A (ru) | (циклопропилфенил)фенилоксаламиды, способ их получения и их применения в качестве лекарственного средства | |
| RU2008105756A (ru) | Производные 1,4-бензотиазепин-1,1-диоксида, способ их получения, лекарственное средство, содержащее эти соединения и их применение в качестве гиполипидемических средств | |
| HRP20110009T1 (hr) | Spoj kojim se aktivira ppar i farmaceutski pripravak koji ga sadrži | |
| KR20040003007A (ko) | 카복스아미드 치환된 페닐우레아 유도체 및 약물로서의이의 제조방법 | |
| RU2005133631A (ru) | Новый дифенилазетидинон с улучшенными физиологическими свойствами, способы его получения, содержащие эти соединения лекарственные средства и их применение | |
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| RU2005129999A (ru) | Диарилциклоалкильные производные, способы их получения и их применение в качестве лекарственного средства | |
| NZ337378A (en) | Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use | |
| JP2005533071A (ja) | カチオン的に置換されたジフェニルアゼチジノン、その製造方法、該化合物を含む医薬およびそれらの使用 | |
| RU2005129109A (ru) | Замещенные производные 3-(бензоилуреидо)тиофена, способ их получения и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080115 |